Canaccord Genuity Cuts Deciphera Pharmaceuticals (DCPH) Price Target to $50.00

Share on StockTwits

Deciphera Pharmaceuticals (NASDAQ:DCPH) had its price objective lowered by Canaccord Genuity from $55.00 to $50.00 in a research note published on Friday morning. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Deciphera Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, February 12th. BidaskClub lowered Deciphera Pharmaceuticals from a hold rating to a sell rating in a report on Saturday, December 22nd. Cantor Fitzgerald reissued a buy rating and issued a $53.00 price objective on shares of Deciphera Pharmaceuticals in a report on Thursday, December 20th. B. Riley lowered Deciphera Pharmaceuticals from a buy rating to a neutral rating in a report on Tuesday, January 1st. Finally, Leerink Swann decreased their price objective on Deciphera Pharmaceuticals from $28.00 to $20.00 and set an underperform rating for the company in a report on Friday, November 16th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $42.11.

Shares of DCPH stock opened at $25.29 on Friday. Deciphera Pharmaceuticals has a 12-month low of $18.55 and a 12-month high of $45.61. The company has a market capitalization of $952.45 million, a P/E ratio of -8.46 and a beta of 3.27. The company has a debt-to-equity ratio of 0.06, a current ratio of 18.46 and a quick ratio of 18.46.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.13). Equities research analysts forecast that Deciphera Pharmaceuticals will post -2.59 EPS for the current fiscal year.

In other Deciphera Pharmaceuticals news, insider Michael Douglas Taylor sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $28.01, for a total value of $47,617.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas Patrick Kelly sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $30.00, for a total value of $45,000.00. The disclosure for this sale can be found here. Insiders sold 198,426 shares of company stock valued at $5,247,846 over the last 90 days. 20.61% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can acquired a new stake in Deciphera Pharmaceuticals in the fourth quarter worth approximately $50,000. Legal & General Group Plc lifted its position in Deciphera Pharmaceuticals by 55.4% in the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after purchasing an additional 587 shares during the period. Bank of America Corp DE lifted its position in Deciphera Pharmaceuticals by 316.1% in the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after purchasing an additional 1,982 shares during the period. MetLife Investment Advisors LLC acquired a new stake in Deciphera Pharmaceuticals in the third quarter worth approximately $235,000. Finally, Rhumbline Advisers lifted its position in Deciphera Pharmaceuticals by 53.6% in the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after purchasing an additional 4,000 shares during the period. Hedge funds and other institutional investors own 57.28% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Recommended Story: Investing strategies using the yield curve

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect Steven Madden, Ltd.  Will Announce Quarterly Sales of $404.18 Million
Zacks: Analysts Expect Steven Madden, Ltd. Will Announce Quarterly Sales of $404.18 Million
Zacks: Analysts Anticipate The GEO Group Inc  to Post $0.47 Earnings Per Share
Zacks: Analysts Anticipate The GEO Group Inc to Post $0.47 Earnings Per Share
Theta Fuel Price Up 4.6% Over Last Week
Theta Fuel Price Up 4.6% Over Last Week
LuckChain  Trading Up 18.6% This Week
LuckChain Trading Up 18.6% This Week
Critical Analysis: SBT Bancorp  & MutualFirst Financial
Critical Analysis: SBT Bancorp & MutualFirst Financial
Critical Survey: Prime Meridian  and Dimeco
Critical Survey: Prime Meridian and Dimeco


© 2006-2019 Ticker Report